24 Dec 2025

Proteomics US lab CAP accredited – extends precision Dx lab

---

17 Dec 2025

US patent secured for PromarkerEso diagnostic test for EAC

---

16 Dec 2025

PromarkerD changes how Doctors manage DKD – study published

---

15 Dec 2025

PromarkerD predicts risk of DKD in Aboriginal Australians

---

12 Dec 2025

Investor presentation – TSN ASX Gems Conference

---

26 Nov 2025

PromarkerD CMS price determination

---

24 Nov 2025

OxiDx test correlates with superior racehorse performance

 

---

21 Nov 2025

AGM Chair’s Address and Company Presentation

---

19 Nov 2025

19/11/2025 Investor presentation – Bell Potter Healthcare Conference

---

12 Nov 2025

Proteomics International receives $2.2m in R&D tax incentive

---

07 Nov 2025

Government grant boost for PromarkerEndo

---

27 Oct 2025

Quarterly Activities Report Sept 2025 – Appendix 4C

---

15 Oct 2025

Initial Directors Interest Notice

---

15 Oct 2025

Collaboration expanded to advance Endometriosis blood test

---

14 Oct 2025

Appointment of Director

---

13 Oct 2025

Notification regarding unquoted securities – PIQ

---

07 Oct 2025

Appointment of Company Secretary

---

01 Oct 2025

Notification regarding unquoted securities

---

01 Oct 2025

Notification of cessation of securities

---

19 Sep 2025

Esophageal cancer test results presented at World Congress

---

18 Sep 2025

Proteomics granted certification for Diagnostics Laboratory

---

16 Sep 2025

Notice of AGM Date

---

09 Sep 2025

Board and Management Transition

---

08 Sep 2025

PromarkerEso precisely detects early stage esophageal cancer

---

27 Aug 2025

Annual Report to Shareholders

---

27 Aug 2025

Appendix 4G and Corporate Governance Statement

---

27 Aug 2025

Preliminary Final Report

---

28 Jul 2025

Quarterly Activities Report June 2025 – Appendix 4C

---

24 Jul 2025

Next-Gen PromarkerD test performance results published

---

14 Jul 2025

OxiDx test detects muscle damage in thoroughbred racehorses

---

08 Jul 2025

Application for quotation of securities

---

07 Jul 2025

Notification of cessation of securities

---

04 Jul 2025

Top 20 Holders and Range of Units for Attaching Options

---

04 Jul 2025

Application for quotation of securities

---

03 Jul 2025

AMA grants reimbursement code for Next-Gen PromarkerD test

---

01 Jul 2025

Funding boost for precision diagnostics Proteomics Facility

---

30 Jun 2025

First patent for endometriosis blood test – granted in Japan

---

23 Jun 2025

Next-gen PromarkerD test system released for predicting DKD

---

20 Jun 2025

PromarkerD launched into the US at major diabetes conference

---

13 Jun 2025

Change of Director’s Interest Notices x 4

---

06 Jun 2025

Proposed issue of securities

---

06 Jun 2025

Supplementary Prospectus

---

05 Jun 2025

A landmark in non-invasive Esophageal Cancer diagnosis

---

05 Jun 2025

$12 million capital raise completed with oversubscribed SPP

---

30 May 2025

Results of Extraordinary General Meeting

---

26 May 2025

PromarkerEndo latest results presented at world congress

---

15 May 2025

Chinese patent granted for OxiDx technology

---

05 May 2025

Share Purchase Plan Offer Booklet

---

02 May 2025

Notice of Extraordinary General Meeting/Proxy Form

---

29 Apr 2025

Notice Under Section 708A

---

29 Apr 2025

Notification regarding unquoted
securities

---

29 Apr 2025

Application for quotation of securities

---

28 Apr 2025

Target Market Determination

---

28 Apr 2025

Options Prospectus

---

24 Apr 2025

Quarterly Activities Report March 2025 – Appendix 4C

---

22 Apr 2025

Proteomics to raise $4.5m through Placement

---

10 Apr 2025

Investor Presentation – JMM Biotech Forum

---

08 Apr 2025

Investor Presentation Morgan Stanley Alpha ex-100 Conference

---

07 Apr 2025

Proteomics appoints Clinical Advisory Board for PromarkerEso

---

28 Mar 2025

Australian patent granted for OxiDx oxidative stress test

---

20 Mar 2025

Investor Presentation – Broker Meets Biotech

---

13 Mar 2025

PromarkerD predictive test for DKD launched in Australia

---

11 Mar 2025

PromarkerD outperforms conventional tests – results published

---

28 Feb 2025

Proteomics opens CLIA certified reference laboratory in USA

---

26 Feb 2025

Interim Financial Report and Appendix 4D

---

04 Feb 2025

Investor Presentation – Euroz Hartleys Healthcare Forum

---

31 Jan 2025

Change of Company Secretary

---

21 Jan 2025

Quarterly Activities Report December 2024 – Appendix 4C

20 Dec 2023

PromarkerD to be available in Chile in expanded deal with Omics Global Solutions

---

23 Nov 2023

AGM Chairman's Address and Investor Presentation

---

22 Nov 2023

US Medicare confirms reimbursement price for PromarkerD

---

09 Nov 2023

Proteomics International receives $1.85 million in R&D tax incentive

---

30 Oct 2023

Investor Presentation - Non-deal Roadshow

---

26 Oct 2023

Quarterly Activities Report September 2023 – Appendix 4C

---

23 Oct 2023

Notice of Annual General Meeting 2023

---

02 Oct 2023

Webinar and Q&A on PromarkerD US CMS price & TGA decision

---

29 Sep 2023

PromarkerD US CMS price & TGA decision

---

08 Sep 2023

Oseophageal cancer test presented

---

04 Sep 2023

OxiDx technology secures Japan patent

---

22 Aug 2023

Preliminary Final Report

---

22 Aug 2023

Corporate Governance Statement and Appendix 4G

---

22 Aug 2023

Annual Report to shareholders

---

14 Aug 2023

Application for quotation of securities - PIQ

---

14 Aug 2023

Exercise of Options

---

25 Jul 2023

Proteomics presents at 17th Bioshares Biotech Summit

---

24 Jul 2023

Quarterly Activities Report and Year Ahead

---

20 Jul 2023

Promarker pipeline - Oesophageal cancer diagnostic test update

---

10 May 2023

Proteomics International & Sonic Healthcare USA sign exclusive licence agreement to market PromarkerD in the US

---

05 May 2023

New diagnostic blood test showcased at world’s premier endometriosis conference

---

03 May 2023

PromarkerD is a potential diagnostic tool to demonstrate the benefits of canagliflozin in diabetic kidney disease

---

27 Apr 2023

Quarterly update March 2023 - Appendix 4C

---

26 Apr 2023

Clinical Advisory Board expanded to support PromarkerD USA and global rollout

---

17 Apr 2023

Proteomics renews its ISO 13485 certification & ISO 17025 accreditation

---

24 Mar 2023

Results of a novel blood test for Endometriosis were presented at international conference

---

01 Mar 2023

US update: PromarkerD licensing negotiations

---

15 Feb 2023

Distribution agreement for PromarkerD in Britain extended

---

02 Feb 2023

Investor Presentation – Euroz Hartleys Healthcare Forum

---

31 Jan 2023

Letter of intent with Sonic Healthcare USA extended

---

31 Jan 2023

Quarterly Update December 2022 – Appendix 4C

---

09 Jan 2023

Letter of intent with Sonic Healthcare USA extended

---

03 Jan 2023

CPT PLA Reimbursement Code Approved in US for PromarkerD

14 Dec 2022

UK NICE publishes Medtech Innovation Briefing on PromarkerD

---

24 Nov 2022

AGM Chairman's Address and Investor Presentation

---

24 Nov 2022

Results of Meeting

---

24 Nov 2022

New Constitution

---

11 Nov 2022

PromarkerD patent granted in Hong Kong

---

04 Nov 2022

Investor Presentation to the Emerging ASX Gems Conference

---

03 Nov 2022

Proteomics International to present at the Emerging ASX Gems Conference

---

31 Oct 2022

Quarterly Update September 2022 – Appendix 4C

---

24 Oct 2022

Exercise of Director Options

---

24 Oct 2022

Change of Directors' Interest Notices x2

---

24 Oct 2022

Application for quotation of securities - PIQ

---

20 Oct 2022

Precision diagnostics facility receives $2m funding boost

---

19 Oct 2022

Notice of Annual General Meeting/Proxy Form

---

17 Oct 2022

Proteomics receives $1.7 million in R&D tax incentive

---

27 Sep 2022

New Oesophageal Cancer Diagnostic shows strong performance

---

30 Aug 2022

Corporate Governance Statement and Appendix 4G

---

30 Aug 2022

Preliminary Final Report – Appendix 4E

---

30 Aug 2022

Annual Report to shareholders

---

29 Aug 2022

OxiDx launched to maximise oxidative stress technology

---

15 Aug 2022

Proteomics raises $8m in successful Placement

---

09 Aug 2022

Proteomics signs binding LOI with Sonic Healthcare USA

---

02 Aug 2022

Clinical Utility Study demonstrates PromarkerD test benefits

---

01 Aug 2022

Potential breakthrough blood test for endometriosis

---

28 Jul 2022

Quarterly Update June 2022 – Appendix 4C

---

25 Jul 2022

European PromarkerD patents expanded beyond diabetes

---

18 Jul 2022

Investor Presentation

---

11 Jul 2022

Application for quotation of securities - PIQ

---

11 Jul 2022

Exercise of Performance Rights

---

30 Jun 2022

Promarker™ pipeline - Endometriosis update Diagnostic readout positive: Study expanded

---

21 Jun 2022

Proteomics International secures exclusive licence to oesophageal cancer biomarkers

---

16 Jun 2022

PromarkerD manufacturing tech-transfer completed – Successful production of components for over 50,000 tests

---

06 Jun 2022

Study shows PromarkerD ability to also predict late-stage kidney decline in type-2 diabetes patients

---

02 Jun 2022

PromarkerD registration submitted to the TGA

---

26 May 2022

Investor Presentation - Jefferies MedTech & Biotech summit

---

12 May 2022

Proteomics International awarded $400,000 to support manufacturing capability in Australia

---

28 Apr 2022

Quarterly Update March 2022 – Appendix 4C

---

12 Apr 2022

New Clinical Advisory Board for PromarkerD global rollout

---

07 Apr 2022

Investor Presentation – Perth Healthcare Summit

---

24 Mar 2022

PromarkerD patent granted in India

---

10 Mar 2022

Investor Presentation

---

24 Feb 2022

Interim Financial Report & Appendix 4D

---

22 Feb 2022

PromarkerD completes ‘pre-assessment’ for Medicare rebate

---

07 Feb 2022

Novel biomarkers identified for Asthma and COPD

---

04 Feb 2022

Unique panel of biomarkers identified for oesophageal cancer

---

28 Jan 2022

Quarterly Update December 2021 – Appendix 4C

16 Dec 2021

Proteomics secures major pharmacokinetic testing contract

---

14 Dec 2021

Proteomics International receives $1.2 million in R&D tax incentive

---

13 Dec 2021

Issue of Equity Incentives to Employees

---

13 Dec 2021

Notification regarding unquoted securities - PIQ

---

25 Nov 2021

AGM Chairman's Address and Investor Presentation

---

25 Nov 2021

Results of Annual General Meeting

---

25 Nov 2021

Final Director's Interest Notice

---

24 Nov 2021

FDA advises regulatory pathway for PromarkerD in US

---

23 Nov 2021

PromarkerD distribution network expands to Britain

---

16 Nov 2021

Director Appointments

---

16 Nov 2021

Proposed issue of Securities

---

16 Nov 2021

Initial Directors' Interest Notices

---

05 Nov 2021

PromarkerD significantly outperforms current standard of care tests in predicting future kidney function decline

---

04 Nov 2021

Application for quotation of securities

---

04 Nov 2021

Exercise of Director Options

---

04 Nov 2021

Change of Directors' Interest Notices

---

03 Nov 2021

Proteomics International awarded $100,000 manufacturing funding

---

28 Oct 2021

Quarterly Update September 2021 – Appendix 4C

---

26 Oct 2021

Proteomics Chairman Terry Sweet to retire at 2021 AGM

---

26 Oct 2021

Notice of Annual General Meeting/Proxy Form

---

18 Oct 2021

Clinical utility study demonstrates benefit of PromarkerD testing

---

30 Aug 2021

Corporate Governance Statement and Appendix 4G

---

30 Aug 2021

Appendix 4E – Preliminary Final Report

---

30 Aug 2021

Annual Report to shareholders

---

12 Aug 2021

Proteomics International contracts Biotem to manufacture PromarkerD test kits

---

11 Aug 2021

Conference presentation - Australasian Diabetes Congress 2021

---

04 Aug 2021

Proteomics to collaborate to validate test for endometriosis

---

02 Aug 2021

Exercise of Options and Secondary Trading Notice

---

02 Aug 2021

Application for quotation of securities

---

30 Jul 2021

Quarterly Update June 2021 – Appendix 4C

---

28 Jul 2021

Manufacturing update and clarification of Abcam engagement

---

22 Jul 2021

Proteomics International engages Abcam to manufacture PromarkerD reagents

---

20 Jul 2021

Investor Presentation

---

16 Jul 2021

Diabetes treatment lowers PromarkerD risk score: Results to be presented at Australasian Diabetes Conference

---

02 Jul 2021

Update on study presented at ADA Conference

---

28 Jun 2021

World-first predictive test for Diabetic Kidney Disease could save $384 billion over 10 years

---

10 Jun 2021

CCO and CFO appointed to bolster executive team

---

18 May 2021

Proteomics secures major analytical services contract

---

13 May 2021

Study demonstrates major economic health benefit of PromarkerD - PromarkerD reimbursement update

---

30 Apr 2021

Issue of Options and Secondary Trading Notice

---

30 Apr 2021

Proposed issue of Securities

---

29 Apr 2021

Proteomics files US FDA 513(g) regulatory submission

---

29 Apr 2021

Quarterly Update March 2021 – Appendix 4C

---

23 Apr 2021

Proteomics International achieves ISO 13485 certification

---

15 Mar 2021

Exercise of Options

---

09 Mar 2021

Investor Presentation

---

26 Feb 2021

Exercise of Options

---

25 Feb 2021

Interim Financial Report and Appendix 4D

---

16 Feb 2021

Response to Price Query

---

8 Feb 2021

Proteomics International seeks FDA approval for PromarkerD

---

28 Jan 2021

Quarterly Update December 2020 – Appendix 4C

---

28 Jan 2021

Results of Meeting

---

28 Jan 2021

Issue of Options and Secondary Trading Notice

---

28 Jan 2021

Update - Proposed issue of Securities - PIQ

26 Nov 2020

AGM Investor Presentation 2020

---

26 Nov 2020

Results of Annual General Meeting 2020

---

12 Nov 2020

Middle East is next market for PromarkerD immunoassay test

---

05 Nov 2020

PromarkerD clinical assay performance results published

---

03 Nov 2020

Proteomics receives 1.1 million in R&D tax incentive

---

03 Nov 2020

Change in substantial holding - Dunlop - PIQ

---

03 Nov 2020

Change in substantial holding - Lipscombe - PIQ

---

02 Nov 2020

Appendix 2A – Completion of Placement

---

28 Oct 2020

Quarterly Update September 2020 – Appendix 4C

---

23 Oct 2020

Proteomics International raises $6m in successful Placement

---

23 Oct 2020

Proposed issue of Securities - PIQ - Unquoted options

---

23 Oct 2020

Proposed issue of Securities - PIQ - Ordinary Fully Paid

---

16 Oct 2020

First distribution agreement for PromarkerD immunoassay

---

12 Oct 2020

PromarkerD international validation study results published

---

09 Oct 2020

Partnership with QIMR Berghofer targets oesophageal cancer

---

29 Sep 2020

Change of Director's Interest Notice

---

31 Aug 2020

Corporate Governance Statement and Appendix 4G

---

31 Aug 2020

Appendix 4E – Preliminary Final Report

---

31 Aug 2020

Annual Report to shareholders

---

26 Aug 2020

Investor Presentation - August 2020

---

18 Aug 2020

Issue of Corporate Advisory Options and Secondary Trading No

---

18 Aug 2020

Proposed issue of Securities – PIQ

---

29 Jul 2020

Quarterly Update June 2020 – Appendix 4C

---

27 Jul 2020

PromarkerD Intellectual Property portfolio expands

---

30 Jun 2020

Updated Trading Policy

---

29 Jun 2020

Appendix 3Y - Directors on-market purchase of shares

---

15 Jun 2020

Appendix 2A - Exercise of Employee Options

---

14 Jun 2020

Big pharma clinical study validates PromarkerD kidney test

---

9 Jun 2020

PIQ Investor Presentation – 9th June 2020

---

25 May 2020

Proteomics International receives COVID-19 research grants

---

28 Apr 2020

Appendix 4C – March 2020 Quarterly Update

---

16 Apr 2020

CE Mark for PromarkerD Immunoassay Kit

---

7 Apr 2020

Diagnostics R&D expanded: the Promarker™ Pipeline

---

31 Mar 2020

Proteomics International expands study with US big pharma

---

27 Mar 2020

Proposed Issue of Securities

---

27 Mar 2020

Issue of Corporate Advisory Options

---

27 Mar 2020

Outcome of Extraordinary General Meeting

---

23 Mar 2020

Proteomics International to patent biomarkers for diagnosis of endometriosis

---

27 Feb 2020

PIQ Half Year Report Appendix 4D

---

10 Feb 2020

PromarkerD presented at Australasian Proteomics conference

---

30 Jan 2020

Appendix 4C - December 2019 Quarterly Update

---

14 Jan 2020

CE Mark for PromarkerD Hub predictive software for DKD